Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE−2 study
We evaluated the effects on glycemic control and body weight of a GLP1-RA in obese type 2 diabetic patients treated with SGLT2-inhibitors and other hypoglycemic agents and/or insulin, in a real-world setting. A cohort of 583 type 2 diabetic outpatients treated with a SGLT2 inhibitor and/or other ant...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Pharmacological Research |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1043661824004626 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846117984741883904 |
|---|---|
| author | Cesare Berra Roberto Manfrini Francesco Bifari Elisa Cipponeri Renata Ghelardi Lucia Centofanti Umberto Mortola Elena Lunati Loredana Bucciarelli Vincenzo Cimino Franco Folli |
| author_facet | Cesare Berra Roberto Manfrini Francesco Bifari Elisa Cipponeri Renata Ghelardi Lucia Centofanti Umberto Mortola Elena Lunati Loredana Bucciarelli Vincenzo Cimino Franco Folli |
| author_sort | Cesare Berra |
| collection | DOAJ |
| description | We evaluated the effects on glycemic control and body weight of a GLP1-RA in obese type 2 diabetic patients treated with SGLT2-inhibitors and other hypoglycemic agents and/or insulin, in a real-world setting. A cohort of 583 type 2 diabetic outpatients treated with a SGLT2 inhibitor and/or other anti-diabetic medications were examined. Because patients had suboptimal glycemic control, the GLP1-RA Dulaglutide was added to ongoing medications. At 6 months, 334 patients had a follow-up visit. Patients were classified in terms of cardiovascular risk (CVR) employing the ESC-EASD 2019 criteria, with the AWARE app. The study’s primary endpoints were changes in: 1) HbA1c level, 2) BMI, and 3) body weight after six months of treatment. Secondary endpoints were evaluation of Dulaglutide addition in type 2 diabetic patients: 1) with more or less than ten years of T2DM; 2) more or less than 75 years of age and in different subgroups of CVR. In the 334 patients which had a 6 months follow-up visit, age was 65,9+9,8; 33.5 % (112) were females and 66.5 % (222) were males. After six months of Dulaglutide treatment, we found a significant reduction in HbA1c levels (8.0+10.5 mmol/mol; p<0.0001) and in body mass index (1.1+1.1 kg/m2; p<0.0001). Efficacy of Dulaglutide was not affected by different CVD risk categories, age and T2DM duration. This real world study provides evidence for significant reductions in HbA1c level, body mass index and body weight in obese type 2 diabetic patients who received add-on treatment with the weekly GLP-1RA, Dulaglutide. |
| format | Article |
| id | doaj-art-809d86e79ffb45e6b4dd60d82ba3bd1d |
| institution | Kabale University |
| issn | 1096-1186 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Pharmacological Research |
| spelling | doaj-art-809d86e79ffb45e6b4dd60d82ba3bd1d2024-12-18T08:47:22ZengElsevierPharmacological Research1096-11862024-12-01210107517Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE−2 studyCesare Berra0Roberto Manfrini1Francesco Bifari2Elisa Cipponeri3Renata Ghelardi4Lucia Centofanti5Umberto Mortola6Elena Lunati7Loredana Bucciarelli8Vincenzo Cimino9Franco Folli10Department of Endocrinology and Metabolic Diseases, IRCCS Multimedica, Milan, Italy; Corresponding author.Department of Endocrinology and Metabolic Diseases, IRCCS Multimedica, Milan, Italy; Departmental Unit of Diabetes and Metabolism, San Paolo Hospital, ASST Santi Paolo e Carlo, Milan, Italy; Endocrinology and Metabolism, Department of Health Science, Università degli Studi di Milano, Milan, ItalyLaboratory of Cell Metabolism and Regenerative Medicine, Department of Medical Biotechnology and Translational Medicine, University of Milan, LITA, Segrate, ItalyDepartment of Endocrinology and Metabolic Diseases, IRCCS Multimedica, Milan, Italy; Department of Biomedical Sciences for Health, University of Milan, Milan, ItalyUOC Coordinamento e Integrazione Rete ASST Melegnano e della MartesanaEndocrinology and Metabolism, Department of Health Science, Università degli Studi di Milano, Milan, ItalyEndocrinology and Metabolism, Department of Health Science, Università degli Studi di Milano, Milan, ItalyDivision of Endocrinology, ASST Fatebenefratelli-Sacco, Milan, ItalyInternational Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, DIBIC, Università di Milano, Milan, ItalyDepartment of Biomedical and Clinical Sciences L. Sacco Endocrinology and Diabetology, Milan, ItalyDepartmental Unit of Diabetes and Metabolism, San Paolo Hospital, ASST Santi Paolo e Carlo, Milan, Italy; Endocrinology and Metabolism, Department of Health Science, Università degli Studi di Milano, Milan, Italy; Corresponding author at: Departmental Unit of Diabetes and Metabolism, San Paolo Hospital, ASST Santi Paolo e Carlo, Milan, Italy.We evaluated the effects on glycemic control and body weight of a GLP1-RA in obese type 2 diabetic patients treated with SGLT2-inhibitors and other hypoglycemic agents and/or insulin, in a real-world setting. A cohort of 583 type 2 diabetic outpatients treated with a SGLT2 inhibitor and/or other anti-diabetic medications were examined. Because patients had suboptimal glycemic control, the GLP1-RA Dulaglutide was added to ongoing medications. At 6 months, 334 patients had a follow-up visit. Patients were classified in terms of cardiovascular risk (CVR) employing the ESC-EASD 2019 criteria, with the AWARE app. The study’s primary endpoints were changes in: 1) HbA1c level, 2) BMI, and 3) body weight after six months of treatment. Secondary endpoints were evaluation of Dulaglutide addition in type 2 diabetic patients: 1) with more or less than ten years of T2DM; 2) more or less than 75 years of age and in different subgroups of CVR. In the 334 patients which had a 6 months follow-up visit, age was 65,9+9,8; 33.5 % (112) were females and 66.5 % (222) were males. After six months of Dulaglutide treatment, we found a significant reduction in HbA1c levels (8.0+10.5 mmol/mol; p<0.0001) and in body mass index (1.1+1.1 kg/m2; p<0.0001). Efficacy of Dulaglutide was not affected by different CVD risk categories, age and T2DM duration. This real world study provides evidence for significant reductions in HbA1c level, body mass index and body weight in obese type 2 diabetic patients who received add-on treatment with the weekly GLP-1RA, Dulaglutide.http://www.sciencedirect.com/science/article/pii/S1043661824004626Type 2 Diabetes MellitusCardiovascular riskAWARE appGlucagon Like Peptide 1 Receptor AgonistsSodium-Glucose Co-Transporter-2 inhibitors |
| spellingShingle | Cesare Berra Roberto Manfrini Francesco Bifari Elisa Cipponeri Renata Ghelardi Lucia Centofanti Umberto Mortola Elena Lunati Loredana Bucciarelli Vincenzo Cimino Franco Folli Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE−2 study Pharmacological Research Type 2 Diabetes Mellitus Cardiovascular risk AWARE app Glucagon Like Peptide 1 Receptor Agonists Sodium-Glucose Co-Transporter-2 inhibitors |
| title | Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE−2 study |
| title_full | Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE−2 study |
| title_fullStr | Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE−2 study |
| title_full_unstemmed | Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE−2 study |
| title_short | Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE−2 study |
| title_sort | improved glycemic and weight control with dulaglutide addition in sglt2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real world setting the aware 2 study |
| topic | Type 2 Diabetes Mellitus Cardiovascular risk AWARE app Glucagon Like Peptide 1 Receptor Agonists Sodium-Glucose Co-Transporter-2 inhibitors |
| url | http://www.sciencedirect.com/science/article/pii/S1043661824004626 |
| work_keys_str_mv | AT cesareberra improvedglycemicandweightcontrolwithdulaglutideadditioninsglt2inhibitortreatedobesetype2diabeticpatientsathighcardiovascularriskinarealworldsettingtheaware2study AT robertomanfrini improvedglycemicandweightcontrolwithdulaglutideadditioninsglt2inhibitortreatedobesetype2diabeticpatientsathighcardiovascularriskinarealworldsettingtheaware2study AT francescobifari improvedglycemicandweightcontrolwithdulaglutideadditioninsglt2inhibitortreatedobesetype2diabeticpatientsathighcardiovascularriskinarealworldsettingtheaware2study AT elisacipponeri improvedglycemicandweightcontrolwithdulaglutideadditioninsglt2inhibitortreatedobesetype2diabeticpatientsathighcardiovascularriskinarealworldsettingtheaware2study AT renataghelardi improvedglycemicandweightcontrolwithdulaglutideadditioninsglt2inhibitortreatedobesetype2diabeticpatientsathighcardiovascularriskinarealworldsettingtheaware2study AT luciacentofanti improvedglycemicandweightcontrolwithdulaglutideadditioninsglt2inhibitortreatedobesetype2diabeticpatientsathighcardiovascularriskinarealworldsettingtheaware2study AT umbertomortola improvedglycemicandweightcontrolwithdulaglutideadditioninsglt2inhibitortreatedobesetype2diabeticpatientsathighcardiovascularriskinarealworldsettingtheaware2study AT elenalunati improvedglycemicandweightcontrolwithdulaglutideadditioninsglt2inhibitortreatedobesetype2diabeticpatientsathighcardiovascularriskinarealworldsettingtheaware2study AT loredanabucciarelli improvedglycemicandweightcontrolwithdulaglutideadditioninsglt2inhibitortreatedobesetype2diabeticpatientsathighcardiovascularriskinarealworldsettingtheaware2study AT vincenzocimino improvedglycemicandweightcontrolwithdulaglutideadditioninsglt2inhibitortreatedobesetype2diabeticpatientsathighcardiovascularriskinarealworldsettingtheaware2study AT francofolli improvedglycemicandweightcontrolwithdulaglutideadditioninsglt2inhibitortreatedobesetype2diabeticpatientsathighcardiovascularriskinarealworldsettingtheaware2study |